Sandoz Group AG
SDZ
Rang in aandelen
#579
Operating globally, Sandoz Group AG specializes in the development, production,... Operating globally, Sandoz Group AG specializes in the development, production, and distribution of generic medications and biosimilar products. The company's portfolio includes the creation and sale of finished dosage forms for small molecule pharmaceuticals, often supplied to other entities. Sandoz is also a significant player in the biotechnology sector, providing protein-based products such as biosimilars and offering specialized manufacturing services within this field. Furthermore, it supplies anti-infective products, including active pharmaceutical ingredients (APIs) and intermediates, with a strong emphasis on antibiotics. Established in 1886, Sandoz maintains its headquarters in Rotkreuz, Switzerland.
Aandeelprijs
$96.21
Marktkapitalisatie
$41.63B
Verandering (1 dag)
1.02%
Verandering (1 jaar)
58.97%
Land
CH
Handel Sandoz Group AG (SDZ)
Categorie
Healthcare
Winst voor Sandoz Group AG (SDZ)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Sandoz Group AG bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Sandoz Group AG van 2020 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2025 | $1.21B | -11,072.73% |
| 2024 | $-11.00M | -108.46% |
| 2023 | $130.00M | -88.20% |
| 2022 | $1.10B | -15.20% |
| 2021 | $1.30B | 85.42% |
| 2020 | $700.85M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | - |
IN
|
